Cite
HARVARD Citation
Moreno, C. et al. (2019). Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet oncology. 20 (1), pp. 43-56. [Online].